Skip to main content
Lotus Pharm logo

Lotus Pharm — Investor Relations & Filings

Ticker · 1795 ISIN · TW0001795003 LEI · 984500BEECDBC04KP716 TW Manufacturing
Open in API
Filings indexed 2,732 across all filing types
Latest filing 2022-12-13 Capital/Financing Update
Country TW Taiwan
Listing TW 1795

About Lotus Pharm

http://www.lotuspharm.com.tw

Lotus Pharmaceutical Co., Ltd. is a global specialty organization focused on the development, manufacturing, and commercialization of high-barrier generic and specialty medicines. The company specializes in complex generics, with a primary focus on oncology, immunology, and addiction treatment. Its portfolio includes technically demanding products such as Lenalidomide, Suboxone, Nintedanib, and Vinorelbine, as well as an advancing pipeline of biosimilars and 505(b)(2) oncology candidates. Utilizing an integrated R&D and manufacturing platform, the company executes a "2x2" growth strategy centered on dual market expansion and product diversification. Its commercial footprint spans over 90 markets globally, maintaining a strong presence in the Asia-Pacific region and the United States. The company prioritizes high technical entry barriers and cost-effective therapeutic solutions to improve global patient access to essential medications.

Recent filings

Filing Released Lang Actions
公告本公司取得Alimta台灣地區產品權利
Capital/Financing Update Classification · 95% confidence The document is a regulatory announcement from a listed company (1795 美時) disclosing the acquisition of product rights (Alimta in Taiwan) from Eli Lilly and Company. It includes details such as transaction amount, date, counterparties, board approval, and accounting firm information. The document is short (1764 characters) and structured as a formal disclosure of a corporate transaction rather than a financial report or detailed analysis. It does not contain financial statements, earnings data, or management discussion. It is a typical capital/financing update announcing a significant asset acquisition and related transaction details. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2022-12-13 Chinese
111年11月內部人持股異動(事後)
Director's Dealing Classification · 95% confidence The document consists of detailed tables listing shareholdings and changes in share ownership by insiders, including directors, general managers, and other senior executives. It includes data on shares held, increases, decreases, and trust shares, with specific references to insider identities and their share transactions. This type of document is characteristic of a Director's Dealing report, which discloses personal share transactions by company directors and executives. There is no indication that this is a full financial report, earnings release, or other types of filings. The document is not a brief announcement or a certification but a detailed insider shareholding disclosure.
2022-12-12 Chinese
111年11月董事會成員及持股
Director's Dealing Classification · 95% confidence The document contains detailed tabular data about shareholdings and pledged shares of company insiders, including directors and senior management. It lists current holdings, pledged shares, and related percentages. The content focuses on insider shareholdings and their changes, which aligns with disclosures about personal share transactions or holdings by company directors and executives. There is no indication of financial results, meeting materials, or regulatory announcements unrelated to insider holdings. The document length is about 4,132 characters, which is sufficient for a detailed insider shareholding report. Therefore, the document best fits the category of Director's Dealing (DIRS).
2022-12-12 Chinese
本公司受邀參加元大證券舉辦之2022年第四季趨勢論壇
Investor Presentation Classification · 90% confidence The document is a brief announcement about the company (1795 美時) participating in a securities forum organized by Yuanta Securities, specifically a Q4 2022 trend forum. It mentions the date, time, and location of the event and states that the company will explain its financial and operational status to institutional investors. The document is short (654 characters) and does not contain any actual financial statements or detailed financial data. It is essentially a notice of an investor presentation event rather than the presentation itself or a detailed report. Therefore, the document fits best as an Investor Presentation (IP) announcement or notice. Given the content and context, the classification is Investor Presentation (IP) with high confidence.
2022-12-09 Chinese
111年11月背書保證與資金貸與
Regulatory Filings Classification · 95% confidence The document is a financial disclosure from a listed company (美時) providing details on loan balances and endorsement guarantees for the current and previous months, including limits and cumulative amounts. The content is a regulatory financial update related to credit and guarantee exposures, but it does not contain comprehensive financial statements or detailed analysis typical of annual or interim reports. The document is short (629 characters) and appears to be a routine regulatory disclosure rather than a full report. It does not fit into categories like Annual Report, Interim Report, or Earnings Release. It is best classified as a Regulatory Filing (RNS), which covers miscellaneous regulatory announcements and compliance disclosures that do not fit other categories.
2022-12-09 Chinese
111年11月營業收入
Regulatory Filings Classification · 90% confidence The document is a summary report of monthly and cumulative net operating revenue figures for a company named 美時, presented in a tabular format with explanations about accounting standards and reporting practices. It contains no detailed financial statements, management discussion, or comprehensive analysis. The length is short (778 characters), and it appears to be a regulatory disclosure of revenue figures rather than a full financial report or earnings release. There is no indication of an earnings announcement or detailed quarterly report, nor is it a notice or announcement of a report publication. Given the nature and length, this fits best as a Regulatory Filing (RNS) which is a general category for miscellaneous regulatory disclosures that do not fit other specific categories.
2022-12-09 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.